Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald(Vancouver General Hospital), Eugene R. Bleecker(Wake Forest University), Parameswaran Nair(St. Joseph’s Healthcare Hamilton), Stephanie Korn(Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie), Ken Ohta(Tokyo National Hospital), Marek Lommatzsch(Universitätsmedizin Rostock), Gary T. Ferguson, William W. Busse(University of Wisconsin–Madison), Peter Barker(AstraZeneca (United States)), Stephanie Sproule(AstraZeneca (United States)), Geoffrey Gilmartin(AstraZeneca (United States)), Viktoría Werkström(AstraZeneca (Sweden)), Magnus Aurivillius(AstraZeneca (Sweden)), Mitchell Goldman(AstraZeneca (United States))
Cited by 1,367
Abstract
Related Papers
No related papers found
Powered by citation graph analysis